02 May 2017

Alligator Bioscience AB Interim report January-March 2017

 

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017.

“In the first quarter of 2017, Alligator continued to advance our promising product portfolio, which includes five immuno-oncology drug programs with first- or best-in-class potential. In particular, we successfully completed the first Phase I study with ADC-1013, our CD40 agonistic immuno-oncology antibody, ahead of time."

Per Norlén

CEO

Q1 in brief

Business highlights

First clinical phase I study with immuno-oncology CD40 agonist antibody ADC-1013 completed in March.

The company has increased the number of employees with 11%, all in R & D.

Second production phase started for ATOR-1015.

Significant events after the reporting period

No significant events have occurred after the reporting period.

Financial summary

Net sales 2.5 (43.4) MSEK.

Operating result for the period -19.1 (24.1) MSEK.

Profit/loss for the period -19.5 (23.6) MSEK.

Earnings per share -0.27 (0.40) SEK.

Cash and cash equivalents 640 (659) MSEK.

1 275 000 (0) warrants have been redeemed to an equal number of shares during the first quarter

Financial summary (Group)

2017 Jan-Mar 2016 Jan-Mar 2016 Jan-Dec
Net sales, TSEK (SEK thousand) 2 523 43 360 58 240
Profit/loss for the period, TSEK -19 502 23 599 -48 356
Cash flow for the period, TSEK -18 849 -21 303 287 135
Cash and cash equivalents, TSEK 639 739 343 718 659 136
Equity ratio, % 98% 95% 96% 
R&D costs as % of operating costs excluding impairments 67,7% 55,2%

64,3%

Earnings per share before dilution, SEK -0.27   -0.80
Earnings per share after dilution, SEK -0.27   -0.80
Average number of employees 38 30 31

For further information, please contact:

Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard) 
E-mail: per.norlen@alligatorbioscience.com

Rein Piir, VP Investor Relations at Alligator 
Telephone: +46 708 537292 
E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO 
Telephone: +46 46 286 42 85 
E-mail: per-olof.schrewelius@alligatorbioscience.com

The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 23 March, 2017.

About Alligator

Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com.


Back to previous page